HF
LCTX icon

Hoxton Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Hoxton Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-328
Closed -$1K – 358
2015
Q2 		$1K Hold
328
– – ﹤0.01% 319
2015
Q1 		$1K Hold
328
– – ﹤0.01% 308
2014
Q4 		$1K Hold
328
– – ﹤0.01% 326
2014
Q3 		$1K Hold
328
– – ﹤0.01% 300
2014
Q2 		$1K Hold
328
– – ﹤0.01% 297
2014
Q1 		$1K Hold
328
– – ﹤0.01% 315
2013
Q4 		$1K Hold
328
– – ﹤0.01% 671
2013
Q3 		$1K Hold
328
– – ﹤0.01% 439
2013
Q2 		$1K Buy
+328
New +$1.05K ﹤0.01% 617

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Hoxton Financial's LCTX Position: Q3 2015 in Review

Hoxton Financial sold out of Lineage Cell Therapeutics (LCTX) in Q3 2015, closing a stake of 328 shares — an estimated $1K sold.

Hoxton Financial first reported a position in LCTX in Q2 2013 and held it in 9 quarters. The position peaked at $1K in Q2 2015. 74 funds tracked by Wall St. Rank hold LCTX as of Q3 2015.

  • Hoxton Financial reported no remaining Lineage Cell Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Hoxton Financial sold 328 Lineage Cell Therapeutics shares in Q3 2015, an estimated $1K.
  • Hoxton Financial first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 9 quarters.
  • Hoxton Financial's Lineage Cell Therapeutics position peaked at $1K in Q2 2015.
  • 74 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2015.

Based on Hoxton Financial's 13F filing for Q3 2015, filed 20 Oct 2015.